Patil has served as the Chief Operating Officer & Chief Scientific Officer of BioKey, Inc., a GMP-certified facility owned by ABVC. 

"Dr. Uttam has exceptional strategic capabilities, an international network, proven operational effectiveness, and strong background in fundraising," ABVC Board said. 

He is also the R&D Manager for an ABVC collaborative program on new plant-based drugs and combination cancer therapies. This experience gives ABVC "solid leadership in plant-based therapeutics."

Patil's employment with ABVC began on June 23, 2023.

"The Board looks forward to realizing his potential in delivering long-term growth and value for all its stakeholders."

Price Action: ABVC shares are trading higher by 7.7% to $0.57 on the last check Monday.